Herring WL, Gallagher ME, Shah N, Morse KC, Mladsi D, Dong OM, Chawla A, Leiding JW, Zhang L, Paramore C, Andemariam B. Cost-effectiveness of lovotibeglogene autotemcel (lovo-cel) gene therapy for patients with sickle cell disease and recurrent vaso-occlusive events in the United States. Pharmacoeconomics. 2024 Jun;42(6):693-714. doi: 10.1007/s40273-024-01385-9
Mladsi D, Hess LM, Barnett CL, Njue A, Huang YJ, Cui ZL, Bowman L. Value of clinical trial narrative data to estimate the costs of adverse event management: a feasibility study. J Med Econ. 2020 Mar;23(3):213-20. doi: 10.1080/13696998.2019.1678479
Barnett CL, Mladsi D, Vredenburg M, Aggarwal K. Cost estimate of platelet transfusion in the United States for patients with chronic liver disease and associated thrombocytopenia undergoing elective procedures. J Med Econ. 2018 Aug;21(8):827-34. doi: 10.1080/13696998.2018.1490301
Nazareth T, Purser M, Bhaila R, Philbin M, Mladsi D. The economic burden of moderate-to-severe multiple sclerosis relapse in the United States: findings from a systematic literature review. Poster presented at the 69th AAN Annual Meeting; April 2017. Boston, MA. [abstract] Neurology. 2017 Apr 18; 88(16 Suppl).
Neighbors DM, Bell TJ, Wilson J, Dodd SL. Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. J Pain Symptom Manage. 2001 Feb 1;21(2):129-43. doi: 10.1016/s0885-3924(00)00247-5.
Neighbors DM, Dodd SL. Re: economic evaluation of fentanyl - Response. J Pain Symptom Manage. 2001 Jan 1;22(1):541-3.
Mauskopf JA, Cates SC, Griffin AD, Neighbors DM, Lamb SC, Rutherford C. Cost-effectiveness of zanamivir for the treatment of influenza in a high-risk population in Australia. Pharmacoeconomics. 2000 Jun;17(6):611-20. doi: 10.2165/00019053-200017060-00007.